Cargando…
Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis
AIMS: Cardiac involvement in systemic amyloidosis is a marker of particularly poor prognosis. Cardiac amyloidosis (CA) is characterized by extracellular amyloid deposits inducing heart failure and symptoms of cardiac microvascular disease. While amyloid deposition is most common in the myocardium bu...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934987/ https://www.ncbi.nlm.nih.gov/pubmed/35060356 http://dx.doi.org/10.1002/ehf2.13792 |
_version_ | 1784671949228605440 |
---|---|
author | Zampiccoli, Emanuel Barthelmes, Jens Kreysing, Leonie Nägele, Matthias P. Nebunu, Delia Haider, Thomas von Eckardstein, Arnold Gerber, Bernhard Schwotzer, Rahel Ruschitzka, Frank Sudano, Isabella Flammer, Andreas J. |
author_facet | Zampiccoli, Emanuel Barthelmes, Jens Kreysing, Leonie Nägele, Matthias P. Nebunu, Delia Haider, Thomas von Eckardstein, Arnold Gerber, Bernhard Schwotzer, Rahel Ruschitzka, Frank Sudano, Isabella Flammer, Andreas J. |
author_sort | Zampiccoli, Emanuel |
collection | PubMed |
description | AIMS: Cardiac involvement in systemic amyloidosis is a marker of particularly poor prognosis. Cardiac amyloidosis (CA) is characterized by extracellular amyloid deposits inducing heart failure and symptoms of cardiac microvascular disease. While amyloid deposition is most common in the myocardium but also seen in pericardium and endocardium, atria, and vasculature, the role of (micro‐)vascular dysfunction in CA pathophysiology remains still elusive. Because vascular function is associated with cardiovascular risk and severity of heart failure and represents a potential therapeutic target in CA, the present study investigated retinal vascular function, flow‐mediated dilatation (FMD), and pulse‐wave analysis and velocity (PWA/PWV) in patients with CA. METHODS AND RESULTS: Flicker‐induced arterial dilatation (FIDa) was measured using dynamic retinal vessel analysis additionally to FMD and PWA/PWV. Thirty‐three patients with CA [age 67 years [interquartile range, IQR, 62, 74], 14 with amyloid light‐chain (AL) and 19 with transthyretin (ATTR) amyloidosis] were prospectively included in this cross‐sectional, observational study and 70 healthy individuals (age 53 years [IQR 39, 67]) served as control. Potential confounders were balanced using entropy balancing propensity score analysis [inverse probability weighting (IPW)]. FIDa was reduced in CA patients (1.52 ± 1.73% vs. 3.09 ± 1.96%, P < 0.001, after IPW). While PWV was increased (8.74 ± 2.34 m/s vs. 7.49 ± 1.65 m/s, P = 0.018, after IPW), no difference in FMD was observed. FIDa was significantly associated with prognostic biomarkers of CA [estimated glomerular filtration rate (r = 0.33; P < 0.001), log‐scaled troponin T (r = −0.49; P < 0.001), and N‐terminal pro‐B‐type natriuretic peptide (r = −0.51; P < 0.001)]. CONCLUSIONS: Retinal vascular function is impaired, associated with cardiac and renal biomarkers of CA severity, and may represent a potential therapeutic target in patients with amyloidosis. |
format | Online Article Text |
id | pubmed-8934987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89349872022-03-24 Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis Zampiccoli, Emanuel Barthelmes, Jens Kreysing, Leonie Nägele, Matthias P. Nebunu, Delia Haider, Thomas von Eckardstein, Arnold Gerber, Bernhard Schwotzer, Rahel Ruschitzka, Frank Sudano, Isabella Flammer, Andreas J. ESC Heart Fail Original Articles AIMS: Cardiac involvement in systemic amyloidosis is a marker of particularly poor prognosis. Cardiac amyloidosis (CA) is characterized by extracellular amyloid deposits inducing heart failure and symptoms of cardiac microvascular disease. While amyloid deposition is most common in the myocardium but also seen in pericardium and endocardium, atria, and vasculature, the role of (micro‐)vascular dysfunction in CA pathophysiology remains still elusive. Because vascular function is associated with cardiovascular risk and severity of heart failure and represents a potential therapeutic target in CA, the present study investigated retinal vascular function, flow‐mediated dilatation (FMD), and pulse‐wave analysis and velocity (PWA/PWV) in patients with CA. METHODS AND RESULTS: Flicker‐induced arterial dilatation (FIDa) was measured using dynamic retinal vessel analysis additionally to FMD and PWA/PWV. Thirty‐three patients with CA [age 67 years [interquartile range, IQR, 62, 74], 14 with amyloid light‐chain (AL) and 19 with transthyretin (ATTR) amyloidosis] were prospectively included in this cross‐sectional, observational study and 70 healthy individuals (age 53 years [IQR 39, 67]) served as control. Potential confounders were balanced using entropy balancing propensity score analysis [inverse probability weighting (IPW)]. FIDa was reduced in CA patients (1.52 ± 1.73% vs. 3.09 ± 1.96%, P < 0.001, after IPW). While PWV was increased (8.74 ± 2.34 m/s vs. 7.49 ± 1.65 m/s, P = 0.018, after IPW), no difference in FMD was observed. FIDa was significantly associated with prognostic biomarkers of CA [estimated glomerular filtration rate (r = 0.33; P < 0.001), log‐scaled troponin T (r = −0.49; P < 0.001), and N‐terminal pro‐B‐type natriuretic peptide (r = −0.51; P < 0.001)]. CONCLUSIONS: Retinal vascular function is impaired, associated with cardiac and renal biomarkers of CA severity, and may represent a potential therapeutic target in patients with amyloidosis. John Wiley and Sons Inc. 2022-01-21 /pmc/articles/PMC8934987/ /pubmed/35060356 http://dx.doi.org/10.1002/ehf2.13792 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Zampiccoli, Emanuel Barthelmes, Jens Kreysing, Leonie Nägele, Matthias P. Nebunu, Delia Haider, Thomas von Eckardstein, Arnold Gerber, Bernhard Schwotzer, Rahel Ruschitzka, Frank Sudano, Isabella Flammer, Andreas J. Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis |
title | Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis |
title_full | Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis |
title_fullStr | Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis |
title_full_unstemmed | Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis |
title_short | Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis |
title_sort | eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934987/ https://www.ncbi.nlm.nih.gov/pubmed/35060356 http://dx.doi.org/10.1002/ehf2.13792 |
work_keys_str_mv | AT zampiccoliemanuel eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis AT barthelmesjens eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis AT kreysingleonie eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis AT nagelematthiasp eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis AT nebunudelia eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis AT haiderthomas eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis AT voneckardsteinarnold eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis AT gerberbernhard eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis AT schwotzerrahel eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis AT ruschitzkafrank eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis AT sudanoisabella eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis AT flammerandreasj eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis |